| Aida Kuri Martinez, MD | |
|
230 Worcester St, Wellesley, MA 02481-5420 | |
| (781) 431-5220 | |
| Not Available |
| Full Name | Aida Kuri Martinez |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 17 Years |
| Location | 230 Worcester St, Wellesley, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366647984 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | L-232902 (Massachusetts) | Secondary |
| 207R00000X | Internal Medicine | 239860 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Partners Healthcare At Home - Home Care | Waltham, MA | Home health agency |
| Newton-wellesley Hospital | Newton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atrius Health Inc | 4789588641 | 1116 |
News Archive
Omega-3 fatty acids are essential, necessarily supplied by the diet and indispensable to brain development.
People with specific brain attributes are more likely than others to benefit from targeted cognitive interventions designed to enhance fluid intelligence, scientists report in a new study. Fluid intelligence is a measure of one's ability to adapt to new situations and solve never-before-seen problems.
Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to 64.
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
› Verified 9 days ago
| Entity Name | Atrius Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871639914 PECOS PAC ID: 4789588641 Enrollment ID: O20031121000582 |
News Archive
Omega-3 fatty acids are essential, necessarily supplied by the diet and indispensable to brain development.
People with specific brain attributes are more likely than others to benefit from targeted cognitive interventions designed to enhance fluid intelligence, scientists report in a new study. Fluid intelligence is a measure of one's ability to adapt to new situations and solve never-before-seen problems.
Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to 64.
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aida Kuri Martinez, MD 230 Worcester St, Wellesley, MA 02481-5420 Ph: (781) 431-5220 | Aida Kuri Martinez, MD 230 Worcester St, Wellesley, MA 02481-5420 Ph: (781) 431-5220 |
News Archive
Omega-3 fatty acids are essential, necessarily supplied by the diet and indispensable to brain development.
People with specific brain attributes are more likely than others to benefit from targeted cognitive interventions designed to enhance fluid intelligence, scientists report in a new study. Fluid intelligence is a measure of one's ability to adapt to new situations and solve never-before-seen problems.
Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to 64.
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
› Verified 9 days ago
Deborah Hadley, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Worcester St, Suite 102, Wellesley, MA 02481 Phone: 617-219-1510 Fax: 617-219-1512 | |
Dr. Burt Whitney Hall, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 65 Walnut St, Suite 590, Wellesley, MA 02481 Phone: 781-237-3395 Fax: 781-237-3397 | |
Ida P Gorenburg, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 230 Worcester St, Internal Medicine, Wellesley, MA 02481 Phone: 781-431-5220 Fax: 781-431-5526 | |
James S Sidel, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4 Falmouth Rd, Wellesley, MA 02481 Phone: 781-237-3057 | |
David John Wenzel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Marino Center For Progressive Health, 372 Washington Street, Wellesley, MA 02481 Phone: 781-235-5200 Fax: 781-235-1103 | |
Dr. Jessica Suzanne Mosher, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 William St Ste G15, Wellesley, MA 02481 Phone: 781-591-4234 Fax: 781-369-9737 | |
Charles C Pao, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 Walnut Street, Suite 102, Wellesley, MA 02481 Phone: 781-943-3000 Fax: 781-943-3037 |